Exton Michael 4

What Happened
Michael Exton, CEO of Lexicon Pharmaceuticals (LXRX), had 503,263 restricted stock units (RSUs) convert into common shares on February 28, 2026. To satisfy tax withholding obligations, the company withheld 204,831 of those shares at $1.47 per share, valued at $301,102. The net shares issued to Exton were approximately 298,432 (503,263 vested − 204,831 withheld). This was a vesting/conversion event, not an open-market purchase or voluntary sale.

Key Details

• Transaction date: February 28, 2026 (reported on Form 4 filed March 3, 2026). Filing appears timely.
• Primary actions: Code M — conversion/exercise of derivative (RSUs converting to shares) for 503,263 shares; Code F — withholding of 204,831 shares at $1.47 to satisfy tax obligations (proceeds reported $301,102).
• Net shares received by insider: ~298,432 shares (503,263 − 204,831).
• Shares owned after transaction: Not reported in the provided data.
• Relevant footnotes from the filing: F1 — each RSU equals a contingent right to one share; F2 — company withheld shares to satisfy tax withholding; F3 — RSUs vest 1/3 on Feb 28 of each of the three years following the grant year.

Context

• This was a routine RSU vesting event and a mandatory tax-withholding disposition, not an open-market sale (i.e., no trading decision by the insider to monetize shares beyond required withholding).
• For retail investors: vesting increases insider ownership but the withheld shares reduce the net increase; tax-withholding dispositions are common and do not by themselves imply a change in insider sentiment.